Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Cancer Research

• Publication date

  2018-01-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-1929PMID 29301829PMCID PMC5856605
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epstein–Barr virus: more than 50 years old and still providing surprises

  2016influential reference
• The Ubiquitin Ligase Itch and Ubiquitination Regulate BFRF1-Mediated Nuclear Envelope Modification for Epstein-Barr Virus Maturation

  2016cited by this paper
• Epstein‐Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin

  2016cited by this paper
• Nasopharyngeal carcinoma.

  2016cited by this paper
• Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing

  2016cited by this paper
• Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase

  2015cited by this paper
• A Large-Scale Seroprevalence of Epstein-Barr Virus in Taiwan

  2015cited by this paper
• Large screen approaches to identify novel malaria vaccine candidates.

  2015cited by this paper
• EBV Persistence--Introducing the Virus.

  2015cited by this paper
• Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease.

  2015cited by this paper
• Epstein–Barr Virus Serology as a Potential Screening Marker for Nasopharyngeal Carcinoma among High-Risk Individuals from Multiplex Families in Taiwan

  2014cited by this paper
• The Rad6/18 Ubiquitin Complex Interacts with the Epstein-Barr Virus Deubiquitinating Enzyme, BPLF1, and Contributes to Virus Infectivity

  2014cited by this paper
• Epstein-Barr Virus Large Tegument Protein BPLF1 Contributes to Innate Immune Evasion through Interference with Toll-Like Receptor Signaling

  2014cited by this paper
• Characterization of ELISA detection of broad‐spectrum anti‐Epstein–Barr virus antibodies associated with nasopharyngeal carcinoma

  2013cited by this paper
• From differences in means between cases and controls to risk stratification: a business plan for biomarker development.

  2013cited by this paper
• Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China.

  2013cited by this paper
• Seroprevalence of Epstein-Barr Virus Infection in U.S. Children Ages 6-19, 2003-2010

  2013cited by this paper
• Fluctuations of Epstein-Barr Virus Serological Antibodies and Risk for Nasopharyngeal Carcinoma: A Prospective Screening Study with a 20-Year Follow-Up

  2011cited by this paper
• Plasmodium immunomics.

  2011cited by this paper
• Epstein-Barr Virus LF2 Protein Regulates Viral Replication by Altering Rta Subcellular Localization

  2010cited by this paper
• Defining the humoral immune response to infectious agents using high-density protein microarrays.

  2010cited by this paper
• Self-Assembly of Epstein-Barr Virus Capsids

  2009cited by this paper
• Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology

  2009cited by this paper
• The Epstein-Barr Virus LF2 Protein Inhibits Viral Replication

  2008cited by this paper
• Lytic cycle switches of oncogenic human gammaherpesviruses.

  2007cited by this paper
• Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma

  2007cited by this paper
• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

  2006cited by this paper
• BFRF1 of Epstein-Barr Virus Is Essential for Efficient Primary Viral Envelopment and Egress

  2005cited by this paper
• Epstein‐Barr virus seroreactivity among unaffected individuals within high‐risk nasopharyngeal carcinoma families in Taiwan

  2004cited by this paper
• Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.

  2004cited by this paper
• Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan.

  2002cited by this paper
• Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men.

  2001cited by this paper
• Antibodies to Epstein‐Barr virus thymidine kinase: A characteristic marker for the serological detection of nasopharyngeal carcinoma

  2001cited by this paper
• Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins.

  1991cited by this paper
• Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas.

  1978cited by this paper
• Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma

  1976cited by this paper
• Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review.

  1975cited by this paper
• Comparison of the anti‐ebv titer and the ebv‐associated membrane reactive and precipitating antibody levels in the sera of burkitt lymphoma and nasopharyngeal carcinoma patients and controls

  1970cited by this paper
• Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx

  1970cited by this paper
• Nasopharyngeal Carcinoma

  1966cited by this paper

• Proteome-Wide Serological Profiling Reveals Broad Elevation of EBV Immunity in Idiopathic Pulmonary Fibrosis

  2026cites this paper
• Evaluation of Anti-BNLF2b Antibody and Epstein–Barr Virus Biomarkers for the Diagnosis of Nasopharyngeal Carcinoma: A Retrospective Study

  2026cites this paper
• Le diagnostic virologique des maladies associées au virus d’Epstein-Barr

  2025cites this paper
• Herpesvirus-associated diseases: biomarkers and advancements in clinical research

  2025cites this paper
• Epstein-Barr Virus (EBV)-Specific Humoral Immune Responses in Health and Disease.

  2025cites this paper
• Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region

  2025cites this paper
• EBV Noncoding RNAs.

  2025cites this paper
• Epstein-Barr Virus Antibody Response Patterns in Endemic and Non-Endemic Cases of Nasopharyngeal Carcinoma.

  2025cites this paper
• Noninvasive nasopharyngeal cancer screening via salivary DNA detection using label-free surface-enhanced Raman spectroscopy.

  2025cites this paper
• Epstein-Barr-virus-specific functional antibody signatures in the context of nasopharyngeal carcinoma development.

  2025cites this paper
• Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas

  2025cites this paper
• Sex differences in anti-EBV antibody responses.

  2025cites this paper
• High IgG titers against EBV glycoprotein 42 correlate with lower risk of nasopharyngeal carcinoma

  2025cites this paper
• Prospective evaluation of the relevance of Epstein–Barr virus antibodies for early detection of nasopharyngeal carcinoma in Chinese adults

  2024influential citation
• Advances in basic and translational research into nasopharyngeal carcinoma

  2024cites this paper
• Structures of Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus virions reveal species-specific tegument and envelope features

  2024cites this paper
• Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial

  2024cites this paper
• The Epstein-Barr virus nuclear antigen 1 variant associated with nasopharyngeal carcinoma defines the sequence criteria for serologic risk prediction.

  2024cites this paper
• A proteome‐wide analysis unveils a core Epstein–Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations

  2024cites this paper
• Multiplex assays reveal anti‐EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma

  2024cites this paper
• Molecular diagnosis of nasopharyngeal carcinoma: Past and future

  2024cites this paper
• Epidemiology of nasopharyngeal carcinoma: current insights and future outlook

  2024cites this paper
• Antibody Profiling of Pan-Cancer Viral Proteome Reveals Biomarkers for Nasopharyngeal Carcinoma Diagnosis and Prognosis

  2024cites this paper
• Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver?

  2023cites this paper
• Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer.

  2023cites this paper
• Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

  2023cites this paper
• Development of a Duplex Serological Multiplex Assay for the Simultaneous Detection of Epstein-Barr Virus IgA and IgG Antibodies in Nasopharyngeal Carcinoma Patients

  2023cites this paper
• Virological Markers in Epstein–Barr Virus-Associated Diseases

  2023cites this paper
• Advances of biomarkers in nasopharyngeal carcinoma's early detection.

  2023cites this paper
• Comparative analysis of the humoral immune response to the EBV proteome across EBV-related malignancies.

  2023cites this paper
• Recommendations for Epstein-Barr virus–based screening for nasopharyngeal cancer in high- and intermediate-risk regions

  2023cites this paper
• A novel causal model for nasopharyngeal carcinoma

  2022cites this paper
• Serological profiling using an Epstein-Barr virus mammalian expression library identifies EBNA1 IgA as a pre-diagnostic marker for nasopharyngeal carcinoma.

  2022cites this paper
• 基于微流控技术的磁免疫荧光法在EB病毒检测中的应用

  2022cites this paper
• Effect of EBV Serology-based Screening Program on NPC Mortality: A Cluster Randomized Controlled Trial

  2022cites this paper
• Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis.

  2022cites this paper
• Association between HLA alleles and Epstein–Barr virus Zta‐IgA serological status in healthy males from southern China

  2021influential citation
• Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

  2021cites this paper
• Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication

  2021cites this paper
• Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high-throughput omics (Review)

  2021cites this paper
• Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma

  2021cites this paper
• Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma

  2021cites this paper
• Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma

  2021cites this paper
• Epstein-Barr virus-based nasopharyngeal carcinoma population screening

  2021cites this paper
• Identifying Epstein-Barr virus peptide sequences associated with differential IgG antibody response: EBV sequences associated with B-cell immunity.

  2021cites this paper
• Herpesvirus ubiquitin deconjugases.

  2021cites this paper
• Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma

  2021cites this paper
• Utility of Epstein-Barr virus (EBV) antibodies as screening markers for nasopharyngeal carcinoma: a narrative review

  2021cites this paper
• Epstein‐Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country

  2020influential citation
• Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology

  2020influential citation
• Carcinoma del rinofaringe

  2020cites this paper
• Prospective assessment of a nasopharyngeal carcinoma risk score in a population undergoing screening

  2020cites this paper
• Evaluation of the antibody response to the EBV proteome in EBV‐associated classical Hodgkin lymphoma

  2020cites this paper
• Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma

  2020cites this paper
• Epidemiology of Virus Infection and Human Cancer.

  2020cites this paper
• Carcinoma de nasofaringe

  2020cites this paper
• Erratum: Correction: Identification of a Novel, EBV-based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan (Clinical cancer research : an official journal of the American Association for Cancer Research (2018) 24 6 (1305-1314))

  2020cites this paper
• A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma

  2020cites this paper
• Epstein-Barr Virus (EBV) Based Nasopharyngeal Carcinoma (NPC) Risk Prediction Scores are Elevated in NPC Multiplex Family Members Compared to the General Population in Taiwan.

  2020influential citation
• Correction: Identification of a Novel, EBV-based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan

  2020cites this paper
• Carcinome du nasopharynx

  2020cites this paper
• Detection of IgG directed against a recombinant form of Epstein-Barr virus BALF0/1 protein in patients with nasopharyngeal carcinoma.

  2019cites this paper
• Conventional and Novel Diagnostic Biomarkers and Approaches for Detection of Nasopharyngeal Carcinoma

  2019cites this paper
• Multi-laboratory assessment of EBV serologic assays: the case for standardization

  2019cites this paper
• Circulating Antibodies against Epstein–Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer

  2019cites this paper
• The Association between the Comprehensive Epstein–Barr Virus Serologic Profile and Endemic Burkitt Lymphoma

  2019cites this paper
• Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization

  2019cites this paper
• Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma

  2019cites this paper
• VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma

  2019cites this paper
• The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis

  2018cites this paper
• Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome

  2018cites this paper
• Validation of Multiplex Serology detecting human herpesviruses 1-5

  2018cites this paper
• Recent advances in the management of nasopharyngeal carcinoma

  2018cites this paper
• Title: Identification of a novel, EBV-based antibody risk stratification signature for early detection of nasopharyngeal carcinoma in Taiwan

  2017cites this paper